{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:52Z","timestamp":1780116712937,"version":"3.54.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Smallpox is an infectious disease caused by the variola virus, and it has a high mortality rate. Historically it has broken out in many countries and it was a great threat to human health. Smallpox was declared eradicated in 1980, and Many countries stopped nation-wide smallpox vaccinations at that time. In recent years the potential threat of bioterrorism using smallpox has led to resumed research on the treatment and prevention of smallpox. Effective ways of preventing and treating smallpox infection have been reported, including vaccination, chemical drugs, neutralizing antibodies, and clinical symptomatic therapies. Antibody treatments include anti-sera, murine monoclonal antibodies, and engineered humanized or human antibodies. Engineered antibodies are homologous, safe, and effective. The development of humanized and genetically engineered antibodies against variola virus via molecular biology and bioinformatics is therefore a potentially fruitful prospect with respect to field application. Natural smallpox virus is inaccessible, therefore most research about prevention and\/or treatment of smallpox were done using vaccinia virus, which is much safer and highly homologous to smallpox. Herein we summarize vaccinia virus epitope information reported to date, and discuss neutralizing antibodies with potential value for field application.<\/jats:p>","DOI":"10.3389\/fmicb.2023.1255935","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:11:40Z","timestamp":1698297100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Functional epitopes and neutralizing antibodies of vaccinia virus"],"prefix":"10.3389","volume":"14","author":[{"given":"Fenghao","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beifen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11912-021-01130-x","article-title":"A new generation of vaccines in the age of immunotherapy","volume":"23","author":"Addeo","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R 49","volume":"79","author":"Aldaz-Carroll","year":"2005","journal-title":"J. Virol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1128\/JVI.00374-07","article-title":"Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6 15","volume":"81","author":"Aldaz-Carroll","year":"2007","journal-title":"J. Virol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.0105-2896.2006.00392.x","article-title":"Immunity and immunological memory following smallpox vaccination","volume":"211","author":"Amanna","year":"2006","journal-title":"Immunol. Rev."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/archdermatol.2010.46","article-title":"Adverse events following smallpox vaccination with ACAM2000 in a military population","volume":"146","author":"Beachkofsky","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin 54","volume":"325","author":"Bell","year":"2004","journal-title":"Virology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1128\/JVI.01797-08","article-title":"Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement 53","volume":"83","author":"Benhnia","year":"2009","journal-title":"J. Virol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine 73","volume":"82","author":"Benhnia","year":"2008","journal-title":"J. Virol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1128\/JVI.00852-08","article-title":"Vaccinia virus l1 protein is required for cell entry and membrane fusion 46","volume":"82","author":"Bisht","year":"2008","journal-title":"J. Virol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1743-422X-2-91","article-title":"Importance of disulphide bonds for vaccinia virus L1R protein function 62","volume":"2","author":"Blouch","year":"2005","journal-title":"Virol. J."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1099\/vir.0.049486-0","article-title":"Transport and stability of the vaccinia virus A34 protein is affected by the A33 protein","volume":"94","author":"Breiman","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1099\/vir.0.020677-0","article-title":"Vaccinia virus B5 protein affects the glycosylation, localization and stability of the A34 protein","volume":"91","author":"Breiman","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1128\/JVI.00906-07","article-title":"Characterization of chimpanzee\/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model 58","volume":"81","author":"Chen","year":"2007","journal-title":"J. Virol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1073\/pnas.0510598103","article-title":"Chimpanzee\/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus 56","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1128\/JVI.72.2.1577-1585.1998","article-title":"A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate 40","volume":"72","author":"Chung","year":"1998","journal-title":"J. Virol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0065-3527(06)66002-8","article-title":"In a nutshell: structure and assembly of the vaccinia virion","volume":"66","author":"Condit","year":"2006","journal-title":"Adv. Virus Res."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice 33","volume":"79","author":"Davies","year":"2005","journal-title":"J. Virol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/pmic.200600926","article-title":"Proteome-wide analysis of the serological response to vaccinia and smallpox 26","volume":"7","author":"Davies","year":"2007","journal-title":"Proteomics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1006\/viro.1993.1302","article-title":"The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence 50","volume":"194","author":"Engelstad","year":"1993","journal-title":"Virology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host 16","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions 19","volume":"78","author":"Fogg","year":"2004","journal-title":"J. Virol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1128\/JVI.00568-08","article-title":"Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge 70","volume":"82","author":"Fogg","year":"2008","journal-title":"J. Virol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4161\/mabs.3.6.17621","article-title":"Antibodies for biodefense 57","volume":"3","author":"Froude","year":"2011","journal-title":"MAbs"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review, part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens 5","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.0042-9007.2004.00397.x","article-title":"Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia 74","volume":"86","author":"Goldsmith","year":"2004","journal-title":"Vox Sang."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies 6","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref28","first-page":"404","article-title":"Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle 77","volume":"8","author":"Haurum","year":"2005","journal-title":"IDrugs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.drudis.2006.05.009","article-title":"Recombinant polyclonal antibodies: the next generation of antibody therapeutics? 78","volume":"11","author":"Haurum","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1086\/520936","article-title":"Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity 69","volume":"196","author":"He","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates 17","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1128\/jvi.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox 75","volume":"78","author":"Hooper","year":"2004","journal-title":"J. Virol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1086\/422999","article-title":"Clinical efficacy of intramuscular vaccinia immune globulin: a literature review","volume":"39","author":"Hopkins","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"12384","DOI":"10.1128\/JVI.01524-08","article-title":"Vaccinia virus A26 and A27 proteins form a stable complex tethered to mature virions by association with the A17 transmembrane protein 68","volume":"82","author":"Howard","year":"2008","journal-title":"J. Virol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.1128\/JVI.73.10.8750-8761.1999","article-title":"Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells 43","volume":"73","author":"Hsiao","year":"1999","journal-title":"J. Virol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/viro.1996.0337","article-title":"Neutralizing epitope on penetration protein of vaccinia virus 31","volume":"220","author":"Ichihashi","year":"1996","journal-title":"Virology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1006\/viro.1994.1405","article-title":"Identification of a vaccinia virus penetration protein 63","volume":"202","author":"Ichihashi","year":"1994","journal-title":"Virology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1128\/JVI.02878-15","article-title":"Linear epitopes in vaccinia virus A27 are targets of protective antibodies induced by vaccination against smallpox","volume":"90","author":"Kaever","year":"2016","journal-title":"J. Virol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"11339","DOI":"10.1128\/JVI.01491-14","article-title":"Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein","volume":"88","author":"Kaever","year":"2014","journal-title":"J. Virol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"D311","DOI":"10.1093\/nar\/gki110","article-title":"Poxvirus bioinformatics resource center: a comprehensive Poxviridae informational and analytical resource","volume":"33","author":"Lefkowitz","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1128\/jvi.74.7.3353-3365.2000","article-title":"Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo 14","volume":"74","author":"Lin","year":"2000","journal-title":"J. Virol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e1004495","DOI":"10.1371\/journal.ppat.1004495","article-title":"Murine anti-vaccinia virus D8 antibodies target different epitopes and differ in their ability to block D8 binding to CS-E","volume":"10","author":"Matho","year":"2014","journal-title":"PLoS Pathog."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.1128\/JVI.00836-12","article-title":"Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5 65","volume":"86","author":"Matho","year":"2012","journal-title":"J. Virol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1074\/jbc.M117.814541","article-title":"Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8","volume":"293","author":"Matho","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e1005148","DOI":"10.1371\/journal.ppat.1005148","article-title":"Structural and functional characterization of anti-A33 antibodies reveal a potent cross-species Orthopoxviruses neutralizer","volume":"11","author":"Matho","year":"2015","journal-title":"PLoS Pathog."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0147-9571(03)00025-0","article-title":"Smallpox vaccination and bioterrorism with pox viruses 70","volume":"26","author":"Mayr","year":"2003","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3851\/IMP1573","article-title":"Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model 76","volume":"15","author":"McCausland","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.virol.2010.10.019","article-title":"Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus 25","volume":"409","author":"Meng","year":"2011","journal-title":"Virology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/v12020138","article-title":"Smallpox in the post-eradication era 70","volume":"12","author":"Meyer","year":"2020","journal-title":"Viruses"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e02155","DOI":"10.1128\/JVI.02155-19","article-title":"Vaccinia virus glycoproteins A33, A34, and B5 form a complex for efficient endoplasmic reticulum to trans-Golgi network transport","volume":"94","author":"Monticelli","year":"2020","journal-title":"J. Virol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.virol.2020.02.004","article-title":"Particle-specific neutralizing activity of a monoclonal antibody targeting the poxvirus A33 protein reveals differences between cell associated and extracellular enveloped virions","volume":"544","author":"Mucker","year":"2020","journal-title":"Virology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ccc.2005.06.004","article-title":"Smallpox","volume":"21","author":"Nafziger","year":"2005","journal-title":"Crit. Care Clin."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/dddt.s3687","article-title":"ACAM 2000: the new smallpox vaccine for United States strategic National Stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des. Devel. Ther."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.virol.2008.08.009","article-title":"Vaccinia virus entry\/fusion complex subunit A28 is a target of neutralizing and protective antibodies 37","volume":"380","author":"Nelson","year":"2008","journal-title":"Virology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1743-422X-10-229","article-title":"Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response","volume":"10","author":"Paran","year":"2013","journal-title":"Virol. J."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox vaccines: Past, present, and future 72","volume":"118","author":"Parrino","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref58","first-page":"762","article-title":"Smallpox and bioterrorism 3","volume":"81","author":"Pennington","year":"2003","journal-title":"Bull. World Health Organ."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm7122e1","article-title":"Use of JYNNEOS (smallpox and Monkeypox vaccine, live, nonreplicating) for Preexposure vaccination of persons at risk for occupational exposure to Orthopoxviruses: recommendations of the advisory committee on immunization practices-United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination 2","volume":"16","author":"Roberts","year":"2008","journal-title":"Trends Microbiol."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1128\/JVI.56.2.482-488.1985","article-title":"Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus 4","volume":"56","author":"Rodriguez","year":"1985","journal-title":"J. Virol."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14787210.2020.1819791","article-title":"An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications","volume":"19","author":"Russo","year":"2021","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen 36","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1128\/jvi.78.5.2357-2366.2004","article-title":"Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene 45","volume":"78","author":"Senkevich","year":"2004","journal-title":"J. Virol."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.virol.2010.05.025","article-title":"The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein 71","volume":"405","author":"Shinoda","year":"2010","journal-title":"Virology"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.virol.2007.06.042","article-title":"Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein 64","volume":"368","author":"Su","year":"2007","journal-title":"Virology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1128\/microbiolspec.PoH-0004-2014","article-title":"History of smallpox and its spread in human populations","volume":"4","author":"Theves","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1128\/JVI.73.11.9098-9109.1999","article-title":"Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus 42","volume":"73","author":"V\u00e1zquez","year":"1999","journal-title":"J. Virol."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1006\/viro.2001.1131","article-title":"The A17L gene product of vaccinia virus is exposed on the surface of IMV 38","volume":"290","author":"Wallengren","year":"2001","journal-title":"Virology"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e106263","DOI":"10.1371\/journal.pone.0106263","article-title":"Development and evaluation of single domain antibodies for vaccinia and the L1 antigen","volume":"9","author":"Walper","year":"2014","journal-title":"PLoS One"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1074\/jbc.M114.547372","article-title":"Vaccinia viral protein A27 is anchored to the viral membrane via a cooperative interaction with viral membrane protein A17","volume":"289","author":"Wang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijid.2005.12.001","article-title":"Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy","volume":"10","author":"Wittek","year":"2006","journal-title":"Int. J. Infect. Dis."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies 32","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.virol.2011.06.029","article-title":"An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies 67","volume":"418","author":"Xu","year":"2011","journal-title":"Virology"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-319-46503-6_4","article-title":"Antibody recognition of Immunodominant vaccinia virus envelope proteins 151","volume":"83","author":"Zajonc","year":"2017","journal-title":"Subcell. Biochem."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1255935\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:11:44Z","timestamp":1698297104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1255935\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":75,"alternative-id":["10.3389\/fmicb.2023.1255935"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2023.1255935","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"article-number":"1255935"}}